Development of hepatitis C virus vaccines: challenges and progress

References

• Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis.5(9), 558–567 (2005).
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J. Gastroenterol.13(17), 2436–2441 (2007).
   PubMed Web of Science ®Google Scholar
• Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med.345(1), 41–52 (2001).
   PubMed Web of Science ®Google Scholar
• Houghton M, Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature436(7053), 961–966 (2005).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR et al. Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med.347(13), 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• Timm J, Roggendorf M. Sequence diversity of hepatitis C virus: implications for immune control and therapy. World J. Gastroenterol.13(36), 4808–4817 (2007).
   PubMed Web of Science ®Google Scholar
• Chevaliez S, Pawlotsky JM. Interferon-based therapy of hepatitis C. Adv. Drug Deliv. Rev.59(12), 1222–1241 (2007).
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology132(5), 1979–1998 (2007).
   PubMed Web of Science ®Google Scholar
• Bartenschlager R, Frese M, Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv. Virus Res.63, 71–180 (2004).
   PubMed Web of Science ®Google Scholar
• Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat. Rev. Microbiol.5(6), 453–463 (2007).
   PubMed Web of Science ®Google Scholar
• Neumann AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy. Science282(5386), 103–107 (1998).
   PubMed Web of Science ®Google Scholar
• Drake JW, Charlesworth B, Charlesworth D, Crow JF. Rates of spontaneous mutation. Genetics148(4), 1667–1686 (1998).
   PubMed Web of Science ®Google Scholar
• Simmonds P. Genetic diversity and evolution of hepatitis C virus 15 years on. J. Gen. Virol.85(Pt 11), 3173–3188 (2004).
   PubMed Web of Science ®Google Scholar
• Keck ZY, Machida K, Lai MM, Ball JK, Patel AH, Foung SK. Therapeutic control of hepatitis C virus: the role of neutralizing monoclonal antibodies. Curr. Top. Microbiol. Immunol.317, 1–38 (2008).
   PubMed Web of Science ®Google Scholar
• Cocquerel L, Voisset C, Dubuisson J. Hepatitis C virus entry: potential receptors and their biological functions. J. Gen. Virol.87(Pt 5), 1075–1084 (2006).
   PubMed Web of Science ®Google Scholar
• Tester I, Smyk-Pearson S, Wang P et al. Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J. Exp. Med.201(11), 1725–1731 (2005).
   PubMedGoogle Scholar
• Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. Hepatology42(1), 104–112 (2005).
   PubMed Web of Science ®Google Scholar
• Cox AL, Mosbruger T, Mao Q et al. Cellular immune selection with hepatitis C virus persistence in humans. J. Exp. Med.201(11), 1741–1752 (2005).
   PubMed Web of Science ®Google Scholar
• Uebelhoer L, Han JH, Callendret B et al. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral fitness. PLoS Pathog.4(9), e1000143 (2008).
   Google Scholar
• Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science285(5424), 110–113 (1999).
   PubMed Web of Science ®Google Scholar
• Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J. Exp. Med.197(5), 633–642 (2003).
   PubMed Web of Science ®Google Scholar
• Hsu M, Zhang J, Flint M et al. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl Acad. Sci. USA100(12), 7271–7276 (2003).
   PubMed Web of Science ®Google Scholar
• Barth H, Liang TJ, Baumert TF. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology44(3), 527–535 (2006).
   PubMed Web of Science ®Google Scholar
• Von HT, Rice CM. Hepatitis C virus entry. J. Biol. Chem.283(7), 3689–3693 (2008).
   Google Scholar
• Evans MJ, Von HT, Tscherne DM et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature446(7137), 801–805 (2007).
   PubMed Web of Science ®Google Scholar
• Haberstroh A, Schnober EK, Zeisel MB et al. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology135(5), 1719–1728 (2008).
   PubMed Web of Science ®Google Scholar
• Pestka JM, Zeisel MB, Blaser E et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc. Natl Acad. Sci. USA104(14), 6025–6030 (2007).
   PubMed Web of Science ®Google Scholar
• Meunier JC, Russell RS, Goossens V et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J. Virol.82(2), 966–973 (2008).
   PubMed Web of Science ®Google Scholar
• Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med.11(7), 791–796 (2005).
   PubMed Web of Science ®Google Scholar
• Zhong J, Gastaminza P, Cheng G et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA102(26), 9294–9299 (2005).
   PubMed Web of Science ®Google Scholar
• Lindenbach BD, Evans MJ, Syder AJ et al. Complete replication of hepatitis C virus in cell culture. Science309(5734), 623–626 (2005).
   PubMed Web of Science ®Google Scholar
• Owsianka AM, Tarr AW, Keck ZY et al. Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J. Gen. Virol.89(Pt 3), 653–659 (2008).
   PubMedGoogle Scholar
• Zeisel MB, Cosset FL, Baumert TF. Host neutralizing responses and pathogenesis of hepatitis C virus infection. Hepatology48(1), 299–307 (2008).
   PubMedGoogle Scholar
• Lavillette D, Morice Y, Germanidis G et al. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol.79(10), 6023–6034 (2005).
   PubMed Web of Science ®Google Scholar
• Von Hahn T, Yoon JC, Alter H et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology132(2), 667–678 (2007).
   PubMed Web of Science ®Google Scholar
• Fafi-Kremer S, Soulier E, Fofana I et al. Viral entry and escape from antibody-mediated C virus variants during liver transplantation. J. Hepatol.48(2), 563 (2008) (Abstract).
   Google Scholar
• Haberstroh A, Schnober EK, Zeisel MB et al. SEKCPea. Neutralizing host reponses in hepatitis C virus infection target viral entry at post-binding steps and membrane fusion. Gastroenterolgy135(5), 1719–1728 (2008).
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu CG, Mihalik K et al. Hepatitis C virus epitope-specific neutralizing antibodies in Igs prepared from human plasma. Proc. Natl Acad. Sci. USA104(20), 8449–8454 (2007).
   Web of Science ®Google Scholar
• Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol.80(5), 2418–2428 (2006).
   PubMed Web of Science ®Google Scholar
• Bartosch B, Verney G, Dreux M et al. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol.79(13), 8217–8229 (2005).
   PubMed Web of Science ®Google Scholar
• Dreux M, Pietschmann T, Granier C et al. High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J. Biol. Chem.281(27), 18285–18295 (2006).
   PubMed Web of Science ®Google Scholar
• Dreux M, Cosset FL. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J. Viral Hepat.14(Suppl. 1), 68–76 (2007).
   Google Scholar
• Zeisel MB, Koutsoudakis G, Schnober EK et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology46(6), 1722–1731 (2007).
   PubMed Web of Science ®Google Scholar
• Falkowska E, Kajumo F, Garcia E, Reinus J, Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol.81(15), 8072–8079 (2007).
   PubMed Web of Science ®Google Scholar
• Helle F, Goffard A, Morel V et al. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol.81(15), 8101–8111 (2007).
   PubMed Web of Science ®Google Scholar
• Timpe JM, Stamataki Z, Jennings A et al. Hepatitis C virus cell–cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology47(1), 17–24 (2008).
   PubMed Web of Science ®Google Scholar
• Wei X, Decker JM, Wang S et al. Antibody neutralization and escape by HIV-1. Nature422(6929), 307–312 (2003).
   PubMed Web of Science ®Google Scholar
• Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature420(6916), 678–682 (2002).
   PubMed Web of Science ®Google Scholar
• Law M, Maruyama T, Lewis J et al. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat. Med.14(1), 25–27 (2008).
   PubMed Web of Science ®Google Scholar
• Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature436(7053), 946–952 (2005).
   PubMed Web of Science ®Google Scholar
• Lechner F, Wong DK, Dunbar PR et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J. Exp. Med.191(9), 1499–1512 (2000).
   PubMed Web of Science ®Google Scholar
• Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J. Exp. Med.194(10), 1395–1406 (2001).
   PubMed Web of Science ®Google Scholar
• Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc. Natl Acad. Sci. USA99(24), 15661–15668 (2002).
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, He XS, Nascimbeni M et al. Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J. Immunol.169(6), 3447–3458 (2002).
   PubMed Web of Science ®Google Scholar
• Weiner AJ, Paliard X, Selby MJ et al. Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J. Virol.75(15), 7142–7148 (2001).
   Google Scholar
• Bassett SE, Guerra B, Brasky K et al. Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology33(6), 1479–1487 (2001).
   PubMed Web of Science ®Google Scholar
• Major ME, Mihalik K, Puig M et al. Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J. Virol.76(13), 6586–6595 (2002).
   Google Scholar
• Shoukry NH, Grakoui A, Houghton M et al. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J. Exp. Med.197(12), 1645–1655 (2003).
   PubMed Web of Science ®Google Scholar
• Nascimbeni M, Mizukoshi E, Bosmann M et al. Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J. Virol.77(8), 4781–4793 (2003).
   PubMed Web of Science ®Google Scholar
• Grakoui A, Shoukry NH, Woollard DJ et al. HCV persistence and immune evasion in the absence of memory T cell help. Science302(5645), 659–662 (2003).
   PubMed Web of Science ®Google Scholar
• Lanford RE, Guerra B, Chavez D et al. Cross-genotype immunity to hepatitis C virus. J. Virol.78(3), 1575–1581 (2004).
   PubMed Web of Science ®Google Scholar
• Bukh J, Thimme R, Meunier JC et al. Previously infected chimpanzees are not consistently protected against reinfection or persistent infection after reexposure to the identical hepatitis C virus strain. J. Virol.82(16), 8183–8195 (2008).
   PubMed Web of Science ®Google Scholar
• Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res.69(3), 129–141 (2006).
   PubMed Web of Science ®Google Scholar
• Urbani S, Amadei B, Fisicaro P et al. Outcome of acute hepatitis C is related to virus-specific CD4 function and maturation of antiviral memory CD8 responses. Hepatology44(1), 126–139 (2006).
   PubMed Web of Science ®Google Scholar
• Kaplan DE, Sugimoto K, Newton K et al. Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. Gastroenterology132(2), 654–666 (2007).
   PubMed Web of Science ®Google Scholar
• Chang KM, Rehermann B, McHutchison JG et al. Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J. Clin. Invest.100(9), 2376–2385 (1997).
   PubMed Web of Science ®Google Scholar
• Weiner A, Erickson AL, Kansopon J et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc. Natl Acad. Sci. USA92(7), 2755–2759 (1995).
   PubMed Web of Science ®Google Scholar
• Erickson AL, Kimura Y, Igarashi S et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity15(6), 883–895 (2001).
   PubMed Web of Science ®Google Scholar
• Timm J, Lauer GM, Kavanagh DG et al. CD8 epitope escape and reversion in acute HCV infection. J. Exp. Med.200(12), 1593–1604 (2004).
   PubMed Web of Science ®Google Scholar
• Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL. Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J. Exp. Med.201(11), 1753–1759 (2005).
   PubMed Web of Science ®Google Scholar
• Neumann-Haefelin C, McKiernan S, Ward S et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology43(3), 563–572 (2006).
   PubMed Web of Science ®Google Scholar
• Urbani S, Boni C, Missale G et al. Virus-specific CD8+ lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J. Virol.76(24), 12423–12434 (2002).
   PubMed Web of Science ®Google Scholar
• Spangenberg HC, Viazov S, Kersting N et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. Hepatology42(4), 828–837 (2005).
   PubMed Web of Science ®Google Scholar
• Sugimoto K, Ikeda F, Stadanlick J, Nunes FA, Alter HJ, Chang KM. Suppression of HCV-specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection. Hepatology38(6), 1437–1448 (2003).
   PubMed Web of Science ®Google Scholar
• Cabrera R, Tu Z, Xu Y et al. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology40(5), 1062–1071 (2004).
   PubMed Web of Science ®Google Scholar
• Boettler T, Spangenberg HC, Neumann-Haefelin C et al. T cells with a CD4+CD25+ regulatory phenotype suppress in vitro proliferation of virus-specific CD8+ T cells during chronic hepatitis C virus infection. J. Virol.79(12), 7860–7867 (2005).
   PubMed Web of Science ®Google Scholar
• Rushbrook SM, Ward SM, Unitt E et al. Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J. Virol.79(12), 7852–7859 (2005).
   PubMed Web of Science ®Google Scholar
• Manigold T, Shin EC, Mizukoshi E et al. Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. Blood107(11), 4424–4432 (2006).
   PubMed Web of Science ®Google Scholar
• Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature439(7077), 682–687 (2006).
   PubMed Web of Science ®Google Scholar
• Day CL, Kaufmann DE, Kiepiela P et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature443(7109), 350–354 (2006).
   PubMed Web of Science ®Google Scholar
• Urbani S, Amadei B, Tola D et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J. Virol.80(22), 11398–11403 (2006).
   PubMed Web of Science ®Google Scholar
• Radziewicz H, Ibegbu CC, Fernandez ML et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol.81(6), 2545–2553 (2007).
   PubMed Web of Science ®Google Scholar
• Bowen DG, Shoukry NH, Grakoui A et al. Variable patterns of programmed death-1 expression on fully functional memory T cells after spontaneous resolution of hepatitis C virus infection. J. Virol.82(10), 5109–5114 (2008).
   Google Scholar
• Forns X, Bukh J, Purcell RH. The challenge of developing a vaccine against hepatitis C virus. J. Hepatol.37(5), 684–695 (2002).
   PubMed Web of Science ®Google Scholar
• Lang K, Weiner DB. Immunotherapy for HCV infection: next steps. Expert. Rev.Vaccines7(7), 915–923 (2008).
   PubMed Web of Science ®Google Scholar
• Inchauspe G, Michel ML. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses. J. Viral Hepat.14(Suppl. 1), 97–103 (2007).
   Google Scholar
• Shiina M, Rehermann B. Hepatitis C vaccines: inducing and challenging memory T cells. Hepatology43(6), 1395–1398 (2006).
   PubMedGoogle Scholar
• Steinmann E, Brohm C, Kallis S, Bartenschlager R, Pietschmann T. Efficient trans-encapsidation of hepatitis C virus RNAs into infectious virus-like particles. J. Virol.82(14), 7034–7046 (2008).
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Ralston R et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA91(4), 1294–1298 (1994).
   PubMed Web of Science ®Google Scholar
• Puig M, Major ME, Mihalik K, Feinstone SM. Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine22(8), 991–1000 (2004).
   PubMed Web of Science ®Google Scholar
• Forns X, Payette PJ, Ma X et al. Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology32(3), 618–625 (2000).
   PubMed Web of Science ®Google Scholar
• Youn JW, Park SH, Lavillette D et al. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. Hepatology42(6), 1429–1436 (2005).
   PubMed Web of Science ®Google Scholar
• Folgori A, Capone S, Ruggeri L et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat. Med.12(2), 190–197 (2006).
   PubMed Web of Science ®Google Scholar
• Kuiken C, Yusim K, Boykin L, Richardson R. The Los Alamos hepatitis C sequence database. Bioinformatics21(3), 379–384 (2005).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Ito S, Wong DT, Liang TJ. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol.72(5), 3827–3836 (1998).
   PubMed Web of Science ®Google Scholar
• Baumert TF, Vergalla J, Satoi J et al. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology117(6), 1397–1407 (1999).
   PubMed Web of Science ®Google Scholar
• Wellnitz S, Klumpp B, Barth H et al. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J. Virol.76(3), 1181–1193 (2002).
   Google Scholar
• Barth H, Schafer C, Adah MI et al. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem.278(42), 41003–41012 (2003).
   PubMed Web of Science ®Google Scholar
• Barth H, Cerino R, Arcuri M et al. Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J. Virol.79(9), 5774–5785 (2005).
   Google Scholar
• Barth H, Ulsenheimer A, Pape GR et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood105(9), 3605–3614 (2005).
   PubMed Web of Science ®Google Scholar
• Barth H, Schnober EK, Neumann-Haefelin C et al. Scavenger receptor class B is required for hepatitis C virus uptake and cross-presentation by human dendritic cells. J. Virol.82(7), 3466–3479 (2008).
   PubMed Web of Science ®Google Scholar
• Lechmann M, Murata K, Satoi J, Vergalla J, Baumert TF, Liang TJ. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology34(2), 417–423 (2001).
   PubMed Web of Science ®Google Scholar
• Murata K, Lechmann M, Qiao M, Gunji T, Alter HJ, Liang TJ. Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proc. Natl Acad. Sci. USA100(11), 6753–6758 (2003).
   PubMed Web of Science ®Google Scholar
• Qiao M, Murata K, Davis AR, Jeong SH, Liang TJ. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology37(1), 52–59 (2003).
   PubMed Web of Science ®Google Scholar
• Elmowalid GA, Qiao M, Jeong SH et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc. Natl Acad. Sci. USA104(20), 8427–8432 (2007).
   PubMed Web of Science ®Google Scholar
• Rollier CS, Paranhos-Baccala G, Verschoor EJ et al. Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology45(3), 602–613 (2007).
   PubMed Web of Science ®Google Scholar
• Mellor AL, Munn DH. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol.4(10), 762–774 (2004).
   PubMed Web of Science ®Google Scholar
• Youn JW, Hu YW, Tricoche N et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J. Virol.82(21), 10896–10905 (2008).
   PubMed Web of Science ®Google Scholar
• Strickland GT, El-Kamary SS, Klenerman P, Nicosia A. Hepatitis C vaccine: supply and demand. Lancet Infect. Dis.8(6), 379–386 (2008).
   PubMed Web of Science ®Google Scholar
• Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J. Hepatol.48(1), 148–162 (2008).
   PubMed Web of Science ®Google Scholar
• Blackard JT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J. Viral Hepat.15(5), 323–330 (2008).
   PubMed Web of Science ®Google Scholar
• Feray C, Gigou M, Samuel D et al. Incidence of hepatitis C in patients receiving different preparations of hepatitis B immunoglobulins after liver transplantation. Ann. Intern. Med.128(10), 810–816 (1998).
   PubMed Web of Science ®Google Scholar
• Logvinoff C, Major ME, Oldach D et al. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl Acad. Sci. USA101(27), 10149–10154 (2004).
   PubMed Web of Science ®Google Scholar
• Meunier JC, Engle RE, Faulk K et al. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl Acad. Sci. USA102(12), 4560–4565 (2005).
   PubMed Web of Science ®Google Scholar
• Davis GL. Hepatitis C immune globulin to prevent HCV recurrence after liver transplantation: chasing windmills? Liver Transpl.12(9), 1317–1319 (2006).
   PubMed Web of Science ®Google Scholar
• Leroux-Roels G, Depla E, Hulstaert F et al. A candidate vaccine based on the hepatitis C E1 protein: tolerability and immunogenicity in healthy volunteers. Vaccine22(23–24), 3080–3086 (2004).
   PubMed Web of Science ®Google Scholar
• Nevens F, Roskams T, Van VH et al. A pilot study of therapeutic vaccination with envelope protein E1 in 35 patients with chronic hepatitis C. Hepatology38(5), 1289–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Klade CS, Wedemeyer H, Berg T et al. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology134(5), 1385–1395 (2008).
   PubMed Web of Science ®Google Scholar
• Firbas C, Jilma B, Tauber E et al. Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects. Vaccine24(20), 4343–4353 (2006).
   PubMed Web of Science ®Google Scholar
• Fournillier A, Gerossier E, Evlache A et al. Therapeutic vaccination against HCV: pre-clinical and clinical evaluation of a novel MVA-based vaccine. Presented at: 15th International Symposium on HCV and Related Viruses, San Antonio, TX, USA, 5–9 October 2008.
   Google Scholar
• Yutani S, Yamada A, Yoshida K et al. Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy. Vaccine25(42), 7429–7435 (2007).
   PubMedGoogle Scholar
• Barth H, Blum HE, Liang TJ, Baumert TF. Novel vaccine strategies. In: State-of-the-Art of Hepatology. Blum HE, Grisham JW, Manns MP (Eds). Kluwer Academic Publishers, Dordrecht, The Netherlands 516–522 (2004).
   Google Scholar